Patents by Inventor Hamed Aissaoui

Hamed Aissaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidine CXCR7 receptor modulators
    Patent number: 11306078
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • NADPH OXIDASE 4 INHIBITORS
    Publication number: 20210395238
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Applicant: ACTELTION PHARMACEUTICALS LTD
    Inventors: Hamed AISSAOUI, Martin BOLLI, Christoph BOSS, Sylvia RICHARD-BILDSTEIN, Patrick SIEBER
  • NADPH oxidase 4 inhibitors
    Patent number: 11136317
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: October 5, 2021
    Assignee: Actelion Pharmaceuticals LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • PIPERIDINE CXCR7 RECEPTOR MODULATORS
    Publication number: 20200385373
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: July 14, 2020
    Publication date: December 10, 2020
    Inventors: Hamed AISSAOUI, Philippe GUERRY, Francois LEHEMBRE, Julien POTHIER, Laetitia POUZOL, Sylvia RICHARD-BILDSTEIN, Shuguang YUAN
  • Piperdine CXCR7 receptor modulators
    Patent number: 10752620
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 25, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Philippe Guerry, Francois Lehembre, Julien Pothier, Laetitia Pouzol, Sylvia Richard-Bildstein, Shuguang Yuan
  • NADPH OXIDASE 4 INHIBITORS
    Publication number: 20200165235
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • NADPH oxidase 4 inhibitors
    Patent number: 10584118
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: March 10, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • Crystalline forms
    Patent number: 10351560
    Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 16, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist, Markus Von Raumer
  • PIPERDINE CXCR7 RECEPTOR MODULATORS
    Publication number: 20190169180
    Abstract: The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 6, 2019
    Inventors: Hamed AISSAOUI, Philippe GUERRY, Francois LEHEMBRE, Julien POTHIER, Laetitia POUZOL, Sylvia RICHARD-BILDSTEIN, Shuguang YUAN
  • Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 10301309
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 28, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • CRYSTALLINE FORMS
    Publication number: 20190047996
    Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 14, 2019
    Applicant: Idorsia Pharmaceuticals Ltd.
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST, Markus VON RAUMER
  • NADPH OXIDASE 4 INHIBITORS
    Publication number: 20180179194
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: June 21, 2016
    Publication date: June 28, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed AISSAOUI, Martin BOLLI, Christoph BOSS, Sylvia RICHARD-BILDSTEIN, Patrick SIEBER
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20180105520
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 19, 2018
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • Azaindole acetic acid derivatives and their use as prostaglandin Dreceptor modulators
    Patent number: 9879006
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: January 30, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 9850241
    Abstract: The present invention relates to azaindolle acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 26, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20170129884
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: March 17, 2015
    Publication date: May 11, 2017
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST
  • Acrylamide derivatives as antimalarial agents
    Patent number: 9637473
    Abstract: The invention relates to novel acrylamide derivatives of the formula I wherein R1, R2, R3, X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Christoph Boss, Claire-Lise Ciana, Thierry Kimmerlin, Romain Siegrist
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20170022196
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: March 16, 2015
    Publication date: January 26, 2017
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST
  • Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 9255090
    Abstract: The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Z, n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 9, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Christoph Boss, Sylvia Richard-Bildstein, Romain Siegrist
  • NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS
    Publication number: 20160024050
    Abstract: The invention relates to novel acrylamide derivatives of the formula (I) wherein R1, R2, R3, X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed AISSAOUI, Christoph BOSS, Claire-Lise CIANA, Thierry KIMMERLIN, Romain SIEGRIST